Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous vs Intermittent ADT on Bone Mineral Density in Prostate Cancer
NCT04248621Phase 4Unknown
- Sponsor
- Wonju Severance Christian Hospital
- Start
- Jan 2020
- Primary completion
- Apr 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of leuprolide, goserelin, triptorelin, degarelix, bicalutamide and 1 more in prostate cancer (PCa) (2 arms), sponsored by Wonju Severance Christian Hospital. Primary endpoint: Change of L-spine total Bone Mineral Density at 12 months. Status: unknown.
02
Drugs
leuprolidegoserelintriptorelindegarelixbicalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04248621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04248621.